Targeting signaling pathways in lung cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 2, 2013, Pages 107-111

  Cho, William C S ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

EGFR; Lung cancer; MTOR; Signaling pathway; VEGF; Wnt

Indexed keywords

AFATINIB; BETA CATENIN; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; NAVELBINE; PAZOPANIB; PEMETREXED; VANDETANIB; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERTENSION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

HUMANS; LUNG NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84872240685     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.729043     Document Type: Review

References (23)

1. Cho WC. Targeting the signaling pathways in cancer therapy. Expert Opin Ther Targets 2012;16:1-3
2. Jia Y, Yang Y, Brock MV, et al. Epigenetic regulation of DACT2, a key component of the Wnt signaling pathway in human lung cancer. J Pathol 2012;doi:10.1002/path.4073
3. Yang L, Chen Y, Cui T, et al. Desmoplakin acts as a tumour suppressor by inhibition of the Wnt/beta-catenin signalling pathway in human lung cancer. Carcinogenesis 2012; doi:10.1093/carcin/bgs226
4. Lee JS, Hur MW, Lee SK, et al. A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer. PLoS One 2012;7(5):e36520
5. Wang Y, Qiu Q, Shen JJ, et al. Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways. Int J Biochem Cell Biol 2012;44:1813-24
6. Tarhini A, Kotsakis A, Gooding W. et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010;16:5900-7
7. Ramalingam SS, Harvey RD, Saba N et al. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 2010;116:3903-9
8. Altorki N, Lane ME, Bauer T, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010;28:3131-7
9. Nikolinakos PG, Altorki N Yankelevitz D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010;70:2171-9
10. Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012;30:1114-21
11. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010;28:193-201
12. Dahlberg SE, Sandler AB, Brahmer JR et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949-54
13. Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled phase 3 trial. Lancet 2011;377:1846-54
14. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol 2012;13:539-48
15. Ramalingam SS, Blackhall F Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;doi:10.1200/JCO.2011.40.9433
16. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL CTONG-0802): A multicentre open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42
17. Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial. J Clin Oncol 2012;20:3002-11
18. Ciuleanu T, Stelmakh L, Cicenas S et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300-8
19. Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): A multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012;13:466-75
20. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42
21. Wu K, House L, Liu W, et al. Personalized targeted therapy for lung cancer. Int J Mol Sci 2012;13:11471-96
22. Vander Heiden MG. Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov 2011;10:671-84
23. Zhang WC, Shyh-Chang N, Yang H et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012;148:259-72